Maravai LifeSciences Holdings, Inc.
MRVI
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.0B
$7.32
▼ -0.68%
P/E
-13.56
Mkt Cap
$2.0B
52-Wk Range
$2.42–$9.42
52-Week Range
$2.42 - $9.42
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 200.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary CleanCap capping technology for mRNA therapeutics with high barriers to entry
- Integrated product portfolio addressing multiple phases of drug development from synthesis to manufacturing quality control
- Strong customer relationships with major pharmaceutical and biotech companies creating switching costs and recurring revenue
- Specialized expertise in nucleic acid chemistry and biologics safety testing with limited direct competitors
Bear Case
1 risk
- Low volatility (beta 0.6).
Growth
Stable outlook
Expansion of mRNA therapeutic pipeline globally with increased investment in vaccine and therapeutic development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+45.2% over 3m
Quality
Stable
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MRVI right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of -$0.02 vs -$0.04 consensus (+54.0% surprise). Revenue of $51.4M vs $48.7M expected (+5.7%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+54.0%
Revenue trend · last 8Q
—
-24%
-27%
-35%
-36%
-12%
+41%
+9%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$65.2M
$56.4M
$46.9M
$47.4M
$41.6M
$49.9M
$65.8M
$51.4M
Margins · last 8Q
Gross
40.1%
Operating
-38.3%
Profit
-24.1%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
0%
Sell
50%
Median Price Target
—
Latest: UBS · Jun 3, 2026
vs Industry
How MRVI stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related